Tecarfarin Anti-Coagulation Trial (TACT)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.

Also called NCT02522221

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Espero Biopharma (from the registry)
Registry
  • NCT NCT02522221
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02522221. Randomized; no masking; primary purpose treatment. Start 2018-06-01 (anticipated); primary completion 2019-03-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tecarfarin Anti-Coagulation Trial (TACT)
Acronym
TACT
Condition
Thromboembolism
Condition
Thrombosis
Intervention (Drug)
Warfarin
Intervention (Drug)
tecarfarin
Lead sponsor
Espero Biopharma (class: industry)

Record details

Record id
cardio:ct-nct02522221
Content hash
1d19308fee89ea592d39bca014b518787897b52711dee05bb759580a6f181757